Vojislav Gligorovski

Vojislav Gligorovski

Auto-generated profile, based on publicly available information

Vojislav Gligorovski

Laboratory of the Physics of Biological Systems, Institute of Physics, École Polytechnique Fédérale de Lausanne, Switzerland (V.G.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Nature Methods
Verified
Journal Article
Closed access
PDF file
JMJun Ma
Jun Ma
RXRonald Xie
Ronald Xie
SAShamini Ayyadhury
Shamini Ayyadhury
CGCheng Ge
Cheng Ge
AGAnubha Gupta
Anubha Gupta
BWBo Wang
Bo Wang

12 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NDNicola Dietler
Nicola Dietler
MMMatthias Minder
Matthias Minder
VGVojislav Gligorovski
Vojislav Gligorovski
AEAugoustina Maria Economou
Augoustina Maria Economou
DJDenis Alain Henri Lucien Joly
Denis Alain Henri Lucien Joly
SRSahand Jamal Rahi
Sahand Jamal Rahi
The identification of cell borders (‘segmentation’) in microscopy images constitutes a bottleneck for large-scale experiments. For the model organismSaccharomyces cerevisiae, current segmentation methods face challenges when cells bud, crowd, or exhibit irregular features. We present a convolutional neural network (CNN) named YeaZ, the underlying training set of high-quality segmented yeast images (>10 000 cells) including mutants, stressed cells, and time courses, as well as a graphical user interface and a web application (www.quantsysbio.com/data-and-software) to efficiently employ, test, and expand the system. A key feature is a cell-cell boundary test which avoids the need for fluorescent markers. Our CNN is highly accurate, including for buds, and outperforms existing methods on benchmark images, indicating it transfers well to other conditions. To demonstrate how efficient large-scale image processing uncovers new biology, we analyze the geometries of ≈2200 wild-type and cyclin mutant cells and find that morphogenesis control occurs unexpectedly early and gradually.

27 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
VGVojislav Gligorovski
Vojislav Gligorovski
ASAhmad Sadeghi
Ahmad Sadeghi
SRSahand Jamal Rahi
Sahand Jamal Rahi
The ability to independently control the expression of different genes is important for quantitative biology. Using budding yeast, we characterize GAL1pr, GALL, MET3pr, CUP1pr, PHO5pr, tetOpr, terminator-tetOpr, Z3EV, blue-light inducible optogenetic systems El222-LIP, El222-GLIP, and red-light inducible PhyB-PIF3. We report kinetic parameters, noise scaling, impact on growth, and the fundamental leakiness of each system using an intuitive unit, maxGAL1. We uncover disadvantages of widely used tools, e.g., nonmonotonic activity of MET3pr and GALL, slow off kinetics of the doxycycline- and estradiol-inducible systems tetOpr and Z3EV, and high variability of PHO5pr and red-light activated PhyB-PIF3 system. We introduce two previously uncharacterized systems: strongLOV, a more light-sensitive El222 mutant, and ARG3pr, which is induced in the absence of arginine or presence of methionine. To demonstrate fine control over gene circuits, we experimentally tune the time between cell cycle Start and mitosis, artificially simulating near-wild-type timing. All strains, constructs, code, and data (https://promoter-benchmark.epfl.ch/) are made available.

12 May 2022 in Nature Physics
Verified
Journal Article
Closed access
PDF file
ASAhmad Sadeghi
Ahmad Sadeghi
RDRoxane Dervey
Roxane Dervey
VGVojislav Gligorovski
Vojislav Gligorovski
MLMarco Labagnara
Marco Labagnara
SRSahand Jamal Rahi
Sahand Jamal Rahi

2 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VGVojislav Gligorovski
Vojislav Gligorovski
MLMarco Labagnara
Marco Labagnara
LSLorenzo Scutteri
Lorenzo Scutteri
MBMarius Blackholm
Marius Blackholm
AMAndreas Möglich
Andreas Möglich
SRSahand Jamal Rahi
Sahand Jamal Rahi
Directed evolution is a powerful method in biological engineering. Current approaches draw on time-invariant selection mechanisms, ideal for evolving steady-state properties such as enzymatic activity or fluorescence intensity. A fundamental problem remains how to continuously evolve dynamic, multi-state, or computational functionalities, e.g., on-off kinetics, state-specific activity, stimulus-responsiveness, or switching and logic capabilities. These require selection pressure on all of the states of a protein of interest (POI) and the transitions between them. We realized that optogenetics and cell cycle oscillations could be leveraged for a novel directed evolution paradigm (‘optovolution’) that is germane for this need: We designed a signaling cascade in budding yeast where optogenetic input switches the POI between off (0) and on (1) states. In turn, the POI controls a Cdk1 cyclin, which in the re-engineered cell cycle system is essential for one cell cycle stage but poisonous for another. Thus, the cyclin must oscillate (1-0-1-0…) for cell proliferation. In this system, evolution can act efficiently on the POI’s different states, input-output relations, and dynamics on the timescale of minutes in every cell cycle. Further, controlling the pacemaker, light, directs and tunes selection pressures. Optovolution is in vivo , continuous, self-selecting, and efficient. We first evolved two optogenetic systems, which relay 0/1 input to 0/1 output: We obtained 19 new variants of the LOV transcription factor El222 that were stronger, less leaky, or green light responsive in vivo . We demonstrate the utility of the latter mutations for orthogonal color-multiplexing with only LOV domains for the first time. Evolving the PhyB-Pif3 optogenetic system, we discovered that loss of YOR1 makes supplementing the chromophore phycocyanobilin (PCB) unnecessary. Finally, we demonstrate the generality of the method by evolving a destabilized rtTA transcription factor, which performs an AND operation between transcriptional and doxycycline input. Optovolution makes coveted, difficult-to-change protein functionalities continuously evolvable.

17 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
YMYahya Mohammadzadeh
Yahya Mohammadzadeh
VGVojislav Gligorovski
Vojislav Gligorovski
OEOlga Egorova
Olga Egorova
GRGabriele Casagrande Raffi
Gabriele Casagrande Raffi
JSJort J. van der Schans
Jort J. van der Schans
MPMichele De Palma
Michele De Palma
Effective antitumor immunity requires dendritic cells (DCs) to internalize, process, and present tumor antigens to T cells. Adoptive transfer of DCs that were loaded ex vivo with tumor antigens has been shown to stimulate antitumor immunity in patients with cancer, but clinical responses have been mixed. To address the limitations of traditional DC-based therapies, we constructed and functionally screened a panel of chimeric antigen receptors (CARs) optimized for expression and activity in DCs. Through this screening, we identified key functional components that guided the development of an inducible platform centered on an instructive chimeric antigen receptor (iCAR). This iCAR enabled DCs to (i) recognize a surface molecule present on cancer cells or their extracellular vesicles (EVs), such as disialoganglioside GD2 (expressed in melanoma and other tumors of neuroectodermal origin) or HER2 (expressed in some epithelial cancers), thereby promoting the acquisition of tumor-derived material containing putative tumor antigens; (ii) undergo immunostimulatory activation to prime antigen-specific T cells via both cross-dressing and cross-presentation; and (iii) transactivate the expression of the therapeutic cytokine interleukin-12 (IL-12) in response to antigen uptake. The iCAR converted melanoma-derived EVs from immune-suppressive to stimulatory cues for DCs in cell culture assays. Moreover, systemic administration of iCAR-DCs enhanced antigen-specific T cells, expanded low-frequency T cell clonotypes, and delayed tumor growth in immunotherapy-resistant melanoma models without the need for ex vivo antigen loading or cell maturation. iCAR-DCs may therefore provide a platform for antigen-agnostic cancer immunotherapy that integrates antigen uptake with programmable DC activation.